Parabilis Medicines
Tracked across 1 events · 7 articles · First seen Jun 10, 2026 · Last active Jun 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Parabilis Medicines, a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 33,500,000 shares of common stock at $20.00 per share, aiming to raise $670 million. The company also granted underwriters…
Impact: Parabilis Medicines priced its upsized initial public offering and a concurrent private placement, raising significant capital to fund its biopharmaceutical development. Its stock is expected to begin trading on the Nasdaq-100 Global Select Market.
Jun 10, 2026 · 7 articles
100
Parabilis Medicines priced initial public offeringParabilis Medicines...
90
Parabilis Medicines agreed to sell shares Regeneron PharmaceuticalsParabilis Medicines...
70
Parabilis Medicines granted underwriters optionParabilis Medicines...
40
Leerink Partners acted as book-running manager Parabilis MedicinesParabilis Medicines...
40
Meritz Securities acted as book-running manager Parabilis MedicinesParabilis Medicines...
40
Evercore acted as book-running manager Parabilis MedicinesParabilis Medicines...
40
Guggenheim Partners acted as book-running manager Parabilis MedicinesParabilis Medicines...
20
LifeSci Capital acted as bookrunning manager Parabilis MedicinesParabilis Medicines...
NEWSDESK
Track Parabilis Medicines live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard